Related Experiment Video

Updated: Mar 25, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.7K

Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes

Mohamed Teleb1, Maryna Popp Switzer2, Sherif Elhanafi3

  • 1Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, USA. mohamed.teleb@ttuhsc.edu.

Current Cardiology Reports
|February 18, 2016
PubMed

Insights

Intensive glycemic control in type 1 diabetes reduces microvascular issues but macrovascular benefits are still debated. Long-term data suggests improved cardiovascular outcomes and mortality in this population.

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Diseases

Background:

  • Diabetes mellitus is a chronic condition with diverse complications, including microvascular and macrovascular diseases.
  • Type 1 diabetes affects 5% of US adults, posing a higher risk for cardiovascular events and mortality.
  • While intensive glycemic control aids microvascular health, its impact on macrovascular complications remains debated.

Purpose of the Study:

  • To review the evidence linking glycemic control to diabetes complications.
  • To specifically examine the effect of glycemic control on cardiovascular mortality in type 1 diabetes.

Main Methods:

  • Review of existing literature and clinical trial data.
  • Analysis of long-term observational follow-up studies.
  • Focus on studies concerning type 1 diabetes and cardiovascular outcomes.

Main Results:

  • Intensive glycemic control consistently reduces microvascular complications.
  • Interventional trials on macrovascular benefits have shown mixed results.
  • Recent long-term observational data indicates potential cardiovascular and mortality benefits not evident in initial trials.

Conclusions:

  • Glycemic control plays a crucial role in managing diabetes complications.
  • Further research and long-term monitoring are essential to fully understand the macrovascular benefits in type 1 diabetes.
  • Evidence suggests a positive impact of glycemic management on cardiovascular mortality in type 1 diabetes over extended periods.

Keywords:
Cardiovascular eventsCardiovascular mortalityDiabetes mellitusHypoglycemiaType 1 DM

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.7K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.9K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
15.0K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.7K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K